Αρχική World News OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and Chemotherapy-Resistant... World News OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and Chemotherapy-Resistant Metastatic Squamous NSCLC Από Ogkologos - 14 Απριλίου, 2026 424 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the stage 1 of the phase III PRESERVE-003 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Why people and culture matter in research 10 Αυγούστου, 2021 Survivor Guest Post: Living Breast-less 18 Ιουνίου, 2019 Tepotinib Shows Activity in Advanced NSCLC with a MET Exon 14... 9 Σεπτεμβρίου, 2020 Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... 16 Σεπτεμβρίου, 2024 Φόρτωση περισσοτέρων HOT NEWS Sotorasib in Combination with Panitumumab Results in Longer PFS in Patients... EMA Adopts Positive Opinion for Pemetrexed Baxter ΗΛΕΚΤΡΟΧΗΜΕΙΟΘΕΡΑΠΕΙΑ: Η ΝΕΑ ΠΡΩΤΟΠΟΡΙΑΚΗ ΠΡΟΣΕΓΓΙΣΗ ΓΙΑ ΘΕΡΑΠΕΙΑ ΟΓΚΩΝ Not Old Enough for Breast Cancer, She Demanded a Mammogram Anyway...
